CRC Research Update — September 27, 2026
Today's colorectal cancer research highlights
braf
A collection of 83 issues
FDG-PET Metabolic Patterns Differ Across RAS, BRAF, and Wild-Type Tumors
Skip to content
The CRC Digest
FDG-PET Metabolic Patterns Differ Across RAS, BRAF, and Wild-Type Tumors
A retrospective study of 106 treatment-naive primary colorectal cancers compared FDG uptake parameters among RAS-mutant, BRAF-mutant, and RAS/BRAF double-wild-type tumors, finding distinct metabolic phenotypes across molecular subgroups. (J Clin Med)
This content is
CRC Research Update — September 21, 2026
Today's colorectal cancer research highlights
Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases
Skip to content
The CRC Digest
◇ RESEARCH
Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases
A comprehensive review reports that hereditary cancer syndromes account for 20-25% of early-onset colorectal cancer cases, with most occurring in the absence of known genetic predispositions. (Oncology Therapy)
This content is informational only and
Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated
Skip to content
The CRC Digest
◇ RESEARCH
Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated
A systematic review finds that most early-onset colorectal cancer cases occur without known genetic predispositions, and emerging evidence points to the gut microbiome as a potential contributor. (Oncology Therapy)
This content is informational only
CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
Critical review outlines biomarker-guided treatment selection in metastatic CRC
Skip to content
The CRC Digest
Critical review outlines biomarker-guided treatment selection in metastatic CRC
A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol)
This content is informational
CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case
Skip to content
The CRC Digest
Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case
A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer)
This